BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 29152756)

  • 1. β-catenin deficiency in hepatocytes aggravates hepatocarcinogenesis driven by oncogenic β-catenin and MET.
    Liang Y; Feng Y; Zong M; Wei XF; Lee J; Feng Y; Li H; Yang GS; Wu ZJ; Fu XD; Feng GS
    Hepatology; 2018 May; 67(5):1807-1822. PubMed ID: 29152756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shp2 deletion in hepatocytes suppresses hepatocarcinogenesis driven by oncogenic β-Catenin, PIK3CA and MET.
    Liu JJ; Li Y; Chen WS; Liang Y; Wang G; Zong M; Kaneko K; Xu R; Karin M; Feng GS
    J Hepatol; 2018 Jul; 69(1):79-88. PubMed ID: 29505847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis.
    Liang B; Zhou Y; Qian M; Xu M; Wang J; Zhang Y; Song X; Wang H; Lin S; Ren C; Monga SP; Wang B; Evert M; Chen Y; Chen X; Huang Z; Calvisi DF; Chen X
    J Hepatol; 2021 Jul; 75(1):120-131. PubMed ID: 33577921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point-mutant β-catenin.
    Tao J; Xu E; Zhao Y; Singh S; Li X; Couchy G; Chen X; Zucman-Rossi J; Chikina M; Monga SP
    Hepatology; 2016 Nov; 64(5):1587-1605. PubMed ID: 27097116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
    Abitbol S; Dahmani R; Coulouarn C; Ragazzon B; Mlecnik B; Senni N; Savall M; Bossard P; Sohier P; Drouet V; Tournier E; Dumont F; Sanson R; Calderaro J; Zucman-Rossi J; Vasseur-Cognet M; Just PA; Terris B; Perret C; Gilgenkrantz H
    J Hepatol; 2018 Jun; 68(6):1203-1213. PubMed ID: 29525529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic potential of N-terminal deletion and S45Y mutant β-catenin in promoting hepatocellular carcinoma development in mice.
    Qiao Y; Xu M; Tao J; Che L; Cigliano A; Monga SP; Calvisi DF; Chen X
    BMC Cancer; 2018 Nov; 18(1):1093. PubMed ID: 30419856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis.
    Shang N; Arteaga M; Zaidi A; Stauffer J; Cotler SJ; Zeleznik-Le NJ; Zhang J; Qiu W
    Hepatology; 2015 Jan; 61(1):214-26. PubMed ID: 25163657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-cell transcriptomics reveals opposing roles of Shp2 in Myc-driven liver tumor cells and microenvironment.
    Chen WS; Liang Y; Zong M; Liu JJ; Kaneko K; Hanley KL; Zhang K; Feng GS
    Cell Rep; 2021 Nov; 37(6):109974. PubMed ID: 34758313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FAK Kinase Activity Is Required for the Progression of c-MET/β-Catenin-Driven Hepataocellular Carcinoma.
    Shang N; Arteaga M; Zaidi A; Cotler SJ; Breslin P; Ding X; Kuo P; Nishimura M; Zhang J; Qiu W
    Gene Expr; 2016; 17(1):79-88. PubMed ID: 27142958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of insulin receptor substrates in the progression of hepatocellular carcinoma.
    Sakurai Y; Kubota N; Takamoto I; Obata A; Iwamoto M; Hayashi T; Aihara M; Kubota T; Nishihara H; Kadowaki T
    Sci Rep; 2017 Jul; 7(1):5387. PubMed ID: 28710407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.
    Zhu C; Ho YJ; Salomao MA; Dapito DH; Bartolome A; Schwabe RF; Lee JS; Lowe SW; Pajvani UB
    J Hepatol; 2021 Mar; 74(3):613-626. PubMed ID: 33038431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
    Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
    J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma.
    Che L; Pilo MG; Cigliano A; Latte G; Simile MM; Ribback S; Dombrowski F; Evert M; Chen X; Calvisi DF
    Cell Cycle; 2017 Mar; 16(6):499-507. PubMed ID: 28118080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Up-regulation of human cervical cancer proto-oncogene contributes to hepatitis B virus-induced malignant transformation of hepatocyte by down-regulating E-cadherin.
    Li J; Dai X; Zhang H; Zhang W; Sun S; Gao T; Kou Z; Yu H; Guo Y; Du L; Jiang S; Zhang J; Zhou Y
    Oncotarget; 2015 Oct; 6(30):29196-208. PubMed ID: 26470691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis.
    Bozkaya G; Korhan P; Cokaklı M; Erdal E; Sağol O; Karademir S; Korch C; Atabey N
    Mol Cancer; 2012 Sep; 11():64. PubMed ID: 22962849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-catenin-activated hepatocellular carcinomas are addicted to fatty acids.
    Senni N; Savall M; Cabrerizo Granados D; Alves-Guerra MC; Sartor C; Lagoutte I; Gougelet A; Terris B; Gilgenkrantz H; Perret C; Colnot S; Bossard P
    Gut; 2019 Feb; 68(2):322-334. PubMed ID: 29650531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wnt/beta-catenin signaling activates and determines hepatic zonal expression of glutathione S-transferases in mouse liver.
    Giera S; Braeuning A; Köhle C; Bursch W; Metzger U; Buchmann A; Schwarz M
    Toxicol Sci; 2010 May; 115(1):22-33. PubMed ID: 20118494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear factor erythroid 2-related factor 2 and β-Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications.
    Tao J; Krutsenko Y; Moghe A; Singh S; Poddar M; Bell A; Oertel M; Singhi AD; Geller D; Chen X; Lujambio A; Liu S; Monga SP
    Hepatology; 2021 Aug; 74(2):741-759. PubMed ID: 33529367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergy between truncated c-Met (cyto-Met) and c-Myc in liver oncogenesis: importance of TGF-beta signalling in the control of liver homeostasis and transformation.
    Amicone L; Terradillos O; Calvo L; Costabile B; Cicchini C; Della Rocca C; Lozupone F; Piacentini M; Buendia MA; Tripodi M
    Oncogene; 2002 Feb; 21(9):1335-45. PubMed ID: 11857077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete response of Ctnnb1-mutated tumours to β-catenin suppression by locked nucleic acid antisense in a mouse hepatocarcinogenesis model.
    Delgado E; Okabe H; Preziosi M; Russell JO; Alvarado TF; Oertel M; Nejak-Bowen KN; Zhang Y; Monga SP
    J Hepatol; 2015 Feb; 62(2):380-7. PubMed ID: 25457204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.